Search Results

Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, announced that it has entered into a clinical collaboration with Merck, to evaluate DF9001, Dragonfly’s EGFR immune engager, in combination with Merck’s anti-PD-1 therapy, KEYTRUDA®, in patients with advanced solid tumors expressing EGFR.

Dragonfly Therapeutics, Inc. announced a new clinical collaboration designed to evaluate and combine DF1001, a HER-2 immune engager developed using Dragonfly’s TriNKET technology platform and Dragonfly’s lead clinical asset, with Trodelvy, Gilead’s Trop-2-directed antibody drug conjugate, in metastatic breast cancer and non-small cell lung cancer.

Dragonfly Therapeutics, Inc. today announced it recently dosed its first patient in a Phase 1/1b study of the Company’s proprietary IL-2 investigational immunotherapy, DF6215, developed for patients with advanced solid tumors.

Dragonfly Therapeutics, Inc. today announced that Bristol Myers Squibb exercised its option to enter into an exclusive license for a sixth TriNKET Immunotherapy drug candidate, that will bring the total drug candidates licensed by Bristol Myers Squibb to seven including Dragonfly’s novel IL12 cytokine DF6002/BMS-986415.

Dragonfly Therapeutics, Inc. announced receipt of a milestone payment following dosing of the first patient in a clinical trial conducted by AbbVie to evaluate ABBV-303, a solid tumor targeting TriNKET®.

Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, announces the first presentation of its DF1001 TriNKET immune engager clinical data at the ASCO 2023 Annual Meeting in Chicago.

Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, today announced it now owns all rights to develop DF6002, its novel interleukin-12 (IL-12) cytokine investigational immunotherapy program, which is in Phase 1 clinical development, with dose escalation progressing successfully in monotherapy and in combination with nivolumab, in the U.S. and in Europe.